Johns Hopkins Medicine press release
In a paper published in the Journal of Clinical Investigation (JCI), researchers at Johns Hopkins Medicine report they may have taken an early step toward a more practical HIV cure. The researchers focused on a patient undergoing cancer treatment and also living with HIV, who after receiving chemotherapy, had a significant reduction in the number of CD4+ T immune cells that contained an HIV provirus ― a key player in HIV’s ability to persist in the body.
The patient in the JCI study received two chemotherapeutic drugs for metastatic lung cancer: paclitaxel and carboplatin. “We suspect that the HIV-infected CD4+ T cells might have been highly susceptible to these drugs and were kept from proliferating in the patient,” says study co-senior author Joel Blankson, M.D., Ph.D., professor of medicine at the Johns Hopkins University School of Medicine. “Our experiment was designed to learn if that’s what really occurred.”
Read the full press release here.
Source : Johns Hopkins Medicine
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.